First Topical CRISPR Gene Therapy Successfully Corrects Disease-Causing Mutations in Human Skin
核心洞察
Researchers at the University of British Columbia have developed the first gene therapy capable of correcting faulty genes when applied directly to human skin using CRISPR (搜索) technology.
The breakthrough treatment successfully corrected the most common genetic mutation behind autosomal recessive congenital ichthyosis (搜索) (ARCI (搜索)), restoring up to 30% of normal skin function in human skin models.
The therapy uses lipid nanoparticles (搜索) combined with laser microablation to deliver gene-editing tools through the skin barrier, showing no off-target effects or systemic distribution.
Researchers at the University of British Columbia, working with colleagues from the Berlin Institute of Health at Charité (搜索) in Germany, have achieved a breakthrough in gene therapy by developing the first treatment capable of correcting disease-causing mutations when applied directly to human skin. The study, published in Cell Stem Cell, demonstrates successful correction of genetic defects in autosomal recessive congenital ichthyosis (搜索) (ARCI (搜索)), a rare and life-threatening inherited skin disorder.
"With this work, we show that it is possible to correct disease-causing mutations in human skin using a topical treatment that is safe, scalable and easy-to-use," said Dr. Sarah Hedtrich, associate professor at UBC's school of biomedical engineering and senior author of the study. "Importantly, the approach corrects the root cause of disease, and our data suggests that a one-time treatment might even be enough to provide a lasting and durable cure."
Targeting a Devastating Rare Disease
ARCI (搜索) affects approximately one in 100,000 people, causing lifelong complications including extremely dry and scaly skin, chronic inflammation and a high risk of infections. There is currently no cure or effective treatment, and patients must manage their symptoms for life with daily bathing and moisturizing routines that can cost families upward of $35,000 annually.
"For many patients, this condition is not only physically painful, but also deeply stigmatizing and isolating," said Dr. Hedtrich. Patients have described themselves as "prisoners, locked inside their house."
The most common form of ARCI (搜索) is caused by mutations in TGM1 (搜索), the gene encoding transglutaminase 1 (搜索), an enzyme essential for cross-linking the outermost layer of the skin barrier. The researchers targeted the most prevalent mutation, a splice-site mutation called c.877-2A>G, which accounts for about a third of all cases.
Breakthrough Delivery Method Overcomes Skin Barrier
The team overcame a major challenge in dermatological gene therapy by developing a novel delivery method using lipid nanoparticle (LNP) technology. These microscopic "bubbles of fat," pioneered by UBC professor Dr. Pieter Cullis and brought to global prominence through mRNA vaccines, carry gene-editing technology into cells.
The researchers use a clinically approved laser to create microscopic, pain-free openings in the outer layers of the skin. This allows the lipid nanoparticles (搜索) to pass through the skin barrier and reach skin stem cells beneath the surface. The pores close again within 16 hours, providing a natural safety mechanism.
"This is a highly targeted, localized approach," said Dr. Hedtrich. "The treatment stays in the skin and we saw no evidence of off-target effects, which is a critical safety milestone."
Clinically Meaningful Results
In testing using models made from living human skin, the team achieved mean on-target gene correction of approximately 12%, with some samples reaching 24%. This translated into roughly 3% restoration of normal TG1 enzyme activity. The treatment restored up to 30% of normal skin function—a level that previous research suggests could be clinically meaningful for returning skin function to normal.
Studies in other genetic skin diseases suggest that restoring as little as 5-10% of wild-type protein levels can alleviate severe symptoms, placing these results well within the clinically relevant range.
The study used a cytosine base editor, eTd-CBE (搜索), to restore the mutant nucleotide to its wild-type form. The team achieved up to 26% on-target editing in patient-derived keratinocytes with no detectable bystander editing—described as among the first demonstrations of therapeutic splice-site repair using a cytosine base editor.
Platform Technology with Broad Applications
"The approach we developed is a platform technology," said Dr. Hedtrich. "It can be readily adapted to treat almost any skin disease." The researchers indicate the treatment strategy could be adapted to many other genetic skin diseases, including epidermolysis bullosa (搜索)—a severe skin blistering condition often called 'butterfly skin'—and potentially more common conditions such as eczema (搜索) or psoriasis (搜索).
The paper frames the approach as applicable to approximately 500 known genetic skin diseases. Different mutations would require different guide RNAs and potentially different base editors, but the delivery system and workflow would remain the same.
Safety Profile and Clinical Translation
Comprehensive safety testing showed promising results. Using fluorescence imaging, qPCR, and metabolic mass spectrometry imaging, the team found no evidence of systemic distribution of either the nanoparticles or the genetic cargo to any organ, even after repeated dosing.
In vivo toxicity studies in mice, conducted under a protocol agreed with Germany's Paul Ehrlich Institute, showed no deaths, no changes in body weight, no skin irritation, no significant immune cell infiltration, and no systemic cytokine elevation—even after repeated dosing.
Single-cell RNA sequencing data showed that about 39% of transfected cells were basal keratinocytes—the layer containing the skin's stem and progenitor cells. If those cells are durably corrected, the edited gene should propagate through natural epidermal turnover, potentially offering a long-lasting cure.
Commercial Development and Regulatory Path
The study was conducted in collaboration with Vancouver-based biotech company NanoVation Therapeutics (搜索), a UBC spin-off focused on developing LNP-based genetic medicines. The technology has been spun out into Epithelica (搜索), which holds Orphan Drug Designation from both the FDA and EMA for ARCI (搜索), unlocking fast-track designation, smaller trial sizes, and priority review.
"From an investor standpoint, the key question is always whether the observed editing efficiency is enough to be clinically meaningful. Our view—and the data support this—is yes," says Gaurav Sadhnani, CTO of Epithelica (搜索) and co-first author of the study.
The researchers are now working with regulatory authorities to define the necessary safety and efficacy studies for clinical testing. "Our goal now is to take this from the lab into first-in-human clinical trials," said Dr. Hedtrich. "We hope this work will ultimately lead to a safe, effective treatment that can transform the lives of patients who currently have no real therapeutic options."